Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11173259
(Pediatric) | TEVA PHARM | Drug delivery device with electronics and power management |
Jan, 2041
(17 years from now) | |
US11266796 | TEVA PHARM | Inhalation device with integrated electronics |
Feb, 2041
(18 years from now) | |
US11266796
(Pediatric) | TEVA PHARM | Inhalation device with integrated electronics |
Aug, 2041
(18 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Jul 9, 2024 |
Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: NA
Dosage: POWDER;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11173259
(Pediatric) | TEVA PHARM | Drug delivery device with electronics and power management |
Jan, 2041
(17 years from now) | |
US11266796 | TEVA PHARM | Inhalation device with integrated electronics |
Feb, 2041
(18 years from now) | |
US11266796
(Pediatric) | TEVA PHARM | Inhalation device with integrated electronics |
Aug, 2041
(18 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Jul 9, 2024 |
New Strength (NS) | Jul 9, 2024 |
Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: NA
Dosage: POWDER;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11173189 | BAXTER HLTHCARE CORP | Daptomycin formulations containing a combination of sorbitol and mannitol |
Mar, 2041
(18 years from now) |
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 25 January, 2022
Treatment: Method of treating a bacterial infection by administering a reconstituted solid formulation of daptomycin containing 31.0 to 59.4% wt total mannitol and sorbitol
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11406623 | GW RES LTD | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
Mar, 2041
(18 years from now) | |
US11160795 | GW RES LTD | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
Mar, 2041
(18 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 28, 2023 |
Orphan Drug Exclusivity (ODE) | Jul 31, 2027 |
New Patient Population (NPP) | Jul 31, 2023 |
Drugs and Companies using CANNABIDIOL ingredient
NCE-1 date: September, 2022
Market Authorisation Date: 28 September, 2018
Treatment: Use for the treatment of seizures associated with tuberous sclerosis complex in patients taking everolimus
Dosage: SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11426348 | PACIRA PHARMS INC | Compositions of bupivacaine multivesicular liposomes |
Jan, 2041
(17 years from now) | |
US11452691 | PACIRA PHARMS INC | Compositions of bupivacaine multivesicular liposomes |
Jan, 2041
(17 years from now) | |
US11357727 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(17 years from now) | |
US11311486 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(17 years from now) | |
US11304904 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(17 years from now) | |
US11033495 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(17 years from now) | |
US11179336 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(17 years from now) | |
US11278494 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Mar 22, 2024 |
Drugs and Companies using BUPIVACAINE ingredient
Market Authorisation Date: 28 October, 2011
Treatment: Method of treating pain, for example, via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia; Method of treating pain, for example, via infiltration for local analgesia or via nerve block, for example, nterscalene brachial plexus for regional analgesia; Method of treating pain, for example, treating postsurgical pain via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia; Method of providing local or regional analgesia via infiltration for local analgesia or via interscalene brachial plexus nerve block or femoral nerve block for regional analgesia; Method of providing postsurgical pain management, for example, via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia
Dosage: INJECTABLE, LIPOSOMAL;INJECTION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11304951 | JANSSEN PHARMS | Dosing regimens associated with extended release paliperidone injectable formulations |
May, 2041
(18 years from now) | |
US11324751 | JANSSEN PHARMS | Dosing regimens associated with extended release paliperidone injectable formulations |
May, 2041
(18 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Strength (NS) | Aug 30, 2024 |
Drugs and Companies using PALIPERIDONE PALMITATE ingredient
Market Authorisation Date: 18 May, 2015
Treatment: Reinitiation of schizophrenia treatment wherein more than 6 months 3 weeks but less than 8 months have elapsed since the last dose; Treatment of schizophrenia by administering a dose up to two weeks before or three weeks after the scheduled six-month dose
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11491125 | AMNEAL | Baclofen formulations and methods of minimizing patient exposure to metabolite variations |
Sep, 2041
(18 years from now) |
Drugs and Companies using BACLOFEN ingredient
Market Authorisation Date: 22 November, 2021
Treatment: Treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity; Treatment of spasticity resulting from spinal cord injuries and other spinal cord diseases
Dosage: GRANULES;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11458095 | CMP DEV LLC | NA |
Feb, 2041
(18 years from now) | |
US11253474 | CMP DEV LLC | Pharmaceutical solution of amlodipine |
Feb, 2041
(18 years from now) |
Drugs and Companies using AMLODIPINE BESYLATE ingredient
Market Authorisation Date: 24 February, 2022
Treatment: Norliqva is indicated for the treatment of hypertension, to lower blood pressure in adults and children 6 years of age and older; Norliqva is indicated for the symptomatic treatment of chronic stable angina; Norliqva is indicated for the treatment of confirmed or suspected vasospastic angina
Dosage: SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11400019 | INNOCOLL | Sustained release drug delivery systems with reduced impurities and related methods |
Jan, 2041
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Feb 1, 2024 |
Drugs and Companies using BUPIVACAINE ingredient
Market Authorisation Date: 01 February, 2021
Treatment: NA
Dosage: SOLUTION, EXTENDED RELEASE;INFILTRATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11266796 | TEVA BRANDED PHARM | Inhalation device with integrated electronics |
Feb, 2041
(18 years from now) |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 31 March, 2015
Treatment: NA
Dosage: POWDER, METERED;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11464735 | ANTARES PHARMA INC | Fixed dose oral testosterone undecanoate compositions and use thereof |
Apr, 2041
(18 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Mar 28, 2025 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 28 March, 2022
Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypogonadism (congenital or acquired).
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11491169 | GILEAD SCIENCES INC | Remdesivir treatment methods |
May, 2041
(18 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Oct 22, 2025 |
New Patient Population (NPP) | Apr 25, 2025 |
New Dosing Schedule (D) | Jan 21, 2025 |
Drugs and Companies using REMDESIVIR ingredient
NCE-1 date: October, 2024
Market Authorisation Date: 22 October, 2020
Treatment: Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 28 days of age and 3 kg) requiring hospitalization and for whom concomitant use of chloroquine, or an analog or sale thereof, is not recommended; Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 28 days of age and 3 kg) and for whom concomitant use of chloroquine, or an analog or salt thereof, is not recommended
Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11318191 | NOVO | GLP-1 compositions and uses thereof |
Feb, 2041
(18 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 5, 2022 |
New Product (NP) | Jun 4, 2024 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 04 June, 2021
Treatment: Method for weight management
Dosage: SOLUTION;SUBCUTANEOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic